Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

VCYT US Equity

Veracyte, Inc.Health Care · Services-Medical Laboratories · CIK 1384101 · FY ends Dec 31
$40.68
-1.40 (-3.33%)
USD · as of 2026-08-18 · marketstack
1 registered study · 1 active

Studies where VCYT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 observational

Held by 13 tracked-famous managers (Artisan Partners Limited Partnership, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, +8 more) · FINRA short interest 4.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: 1 congress / 0 executive

StudyPhaseStatusConditionsEnrollmentPrimary completionUpdated
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab ClassifierNCT06426628observationalNumber of invasive diagnostic proceduresRecruitingPulmonary Nodule, Solitary, Lung Cancer2,4002024-12-312024-11-13

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19